Meeting
2018 Genitourinary Cancers Symposium
Detection of actionable BRAF missense mutations by ctDNA-based genomic analysis in prostate cancer.
Authors
Malshundria Prophet
Medical University of South Carolina, Charleston, SC, US
Malshundria Prophet , Kun Xiao , Theodore Stewart Gourdin , Rebecca J Nagy , Lesli Ann Kiedrowski , Elisa Ledet , Guru Sonpavde , A. Oliver Sartor , Michael B. Lilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 306)
DOI
10.1200/JCO.2018.36.6_suppl.306
Abstract #
306
Poster Bd #
B17
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).
First Author: John H. Strickler
Poster
2019 Genitourinary Cancers Symposium
Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA).
First Author: Pannaga G. Malalur
Poster
2018 Genitourinary Cancers Symposium
Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.
First Author: Bryce Raymon Christensen
Poster
2024 ASCO Annual Meeting
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.
First Author: April K.S. Salama